Gene expression markers for colorectal cancer prognosis
Inventors
Cowens, Wayne • Baker, Joffre B. • Clark, Kim • Hackett, James • Watson, Drew • Paik, Soonmyung
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-8153378-B2
Publication Date
2012-04-10
Expiration Date
Abstract
A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.
Core Innovation
The invention relates to predicting clinical outcome for a human subject diagnosed with colorectal cancer following surgical resection. The method includes determining a normalized expression level of an RNA transcript of FAP, or an expression product thereof, in a tumor sample comprising cancer cells obtained from the subject, and comparing the normalized FAP expression level to gene expression data obtained from colorectal cancer reference samples comprising cancer cells derived from patients with colorectal cancer.
For prediction of clinical outcome, the normalized FAP expression level is negatively correlated with an increased likelihood of a positive clinical outcome. The invention therefore predicts the likelihood of a positive clinical outcome for the subject by using this negative correlation.
The invention also relates to predicting recurrence after surgical resection in a human subject diagnosed with Dukes B (stage II) or Dukes C (stage III) colorectal cancer. For recurrence prediction, the normalized FAP expression level is positively correlated with an increased likelihood of recurrence of colorectal cancer, and the method predicts the likelihood of recurrence by using this positive correlation.
Claims Coverage
Two independent method claims are identified. Both claims share a core predictive framework based on normalized FAP RNA transcript expression, or an expression product thereof, in tumor samples compared to colorectal cancer reference samples, with claim-specific correlation direction and outcome type.
Normalized FAP expression compared to colorectal cancer reference data for positive clinical outcome prediction
Determining a normalized expression level of an RNA transcript of FAP, or an expression product thereof, in a tumor sample comprising cancer cells obtained from the human subject after surgical resection, and predicting a likelihood of a positive clinical outcome by comparing the normalized FAP expression level to gene expression data obtained from colorectal cancer reference samples comprising cancer cells derived from patients with colorectal cancer, wherein the normalized FAP expression level is negatively correlated with an increased likelihood of a positive clinical outcome.
Normalized FAP expression compared to colorectal cancer reference data for recurrence likelihood prediction in Dukes B/C
Determining a normalized expression level of an RNA transcript of FAP, or an expression product thereof, in a tumor sample comprising cancer cells obtained from a human subject diagnosed with Dukes B (stage II) or Dukes C (stage III) colorectal cancer after surgical resection, and predicting a likelihood of recurrence by comparing the normalized FAP expression level to gene expression data obtained from colorectal cancer reference samples comprising cancer cells derived from patients with colorectal cancer, wherein the normalized FAP expression level is positively correlated with an increased likelihood of recurrence of colorectal cancer.
Across the two independent claims, the claim coverage centers on measuring normalized FAP in a post-surgical colorectal cancer tumor sample, comparing it to colorectal cancer reference sample gene expression data, and using the direction of correlation to predict clinical outcome or recurrence likelihood.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Predicting clinical outcome for a human subject diagnosed with colorectal cancer following surgical resection of the cancer.
Predicting the likelihood of recurrence of colorectal cancer following surgical resection in a human subject diagnosed with Dukes B (stage II) or Dukes C (stage III) colorectal cancer.
Interested in licensing this patent?